MK-677 (Ibutamoren)

Overview

MK-677 (ibutamoren) occupies a unique position: it is technically not a peptide (it’s a small molecule GHSR agonist) but belongs pharmacologically to the GH secretagogue family. Its oral bioavailability distinguishes it fundamentally from all injectable GH secretagogues, making it the most convenient GH-stimulating option.

Phase 2 Trial Data

MK-677 has completed multiple Phase 2 trials with reasonably consistent findings: sustained GH and IGF-1 elevation, improved lean mass (particularly in frail elderly), some bone density benefit, and improved sleep architecture. These are more robust findings than most other non-approved peptides, explaining continued pharmaceutical interest.

The Cancer Concern

The IGF-1 elevation produced by MK-677 raises a theoretical concern: IGF-1 is a mitogenic growth factor, and elevated IGF-1 is epidemiologically associated with some cancers. Whether the magnitude and pattern of MK-677-induced IGF-1 elevation translates to increased cancer risk is not established, but it represents a meaningful theoretical risk requiring more long-term safety data.

Market Reality

MK-677 is sold openly online as a “research chemical,” marketed heavily to bodybuilders and anti-aging seekers. The FDA has sent warning letters to companies marketing it for human use. This regulatory status creates a consumer risk landscape of uncertain product quality and standardization.